Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Neuromuscul Disord. 2013 Nov 15;24(3):227–240. doi: 10.1016/j.nmd.2013.11.001

Fig. 2.

Fig. 2

SSBP3 missplicing in neuromuscular diseases. (A) Splice Index (SI) for each probe used in the original array analysis. Exon 6 is included more frequently in DM and NMD than in normal muscle. (B) Assay design for quantitative RT-PCR validation: primers are indicated by arrows; alternative exon 6 is shown in grey. (C) Inclusion indices (Inclusion/Total) from quantitative fluorescent RT-PCR. (D) Kruskal-Wallis plot of isoform ratios, p-value=0.0023. t-test p-values are shown below groups. (E–F) Western blots showing overall reduced protein expression of SSBP3 in DM1 (E) and, to a lesser extent, DM2 (F) compared to normal skeletal muscle. The same normal control is used on both blots. DM samples are different from those used for RT-PCR validation. CBB, Coomassie brilliant blue staining.